Multichannel
How US pharma is charting a new course in a changed world
Post-Trump and post pandemic, pharma in the US is eyeing emerging commercial and clinical opportunities, but must reckon with potential storms ahead
Clinical
Lowering the patient burden in clinical trials
An estimated one in five clinical trials is terminated early, up to 90 per cent fail to hit recruitment targets on time and many...
Clinical
Is COVID the gamechanger for decentralized trials?
The shortcomings of the current model for clinical research are well documented. It costs around $26,000 to enroll the average trial...
Latest
-
-
Medical
Redfining the role of the MSL in a changed world
MSLs will need to respond to the growing demands being placed on them in the new normal by adopting new approaches, capabilities and skill sets -
Commercial
Accelerating commercial success in CAGT
To build on the successes thus far in cell and gene therapy, pharma must foster further payer, physician and patient buy-in -
Clinical
Lowering the patient burden in clinical trials
Closer relationships with patients and a better understanding of what matters to them will show the way improving their experience of trials -
Clinical
Is COVID the gamechanger for decentralized trials?
There is a golden opportunity to deliver clinical trial innovation post-pandemic given healthcare’s appetite for new approaches, such as virtual patient consults and more efficient trial designs
Most Popular
Izzy Gladstone, (Feb 11, 2021)
To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021
Izzy Gladstone, (Feb 17, 2021)
Johanna Friedl-Naderer, President, Europe, Canada & Partner Markets, Biogen on how collaboration between governments and industry can lead to better patient outcomes.
Andrew Stone, (Feb 22, 2021)
Pharma can improve outcomes, products and HCP relationships using technology to capture patients’ day-to-day experience of their disease
Opinion
Jill Donahue, (Mar 11, 2021)
This pharma leader worked in a war zone. Now he’s using the same tactics to navigate the pandemic
Jill Donahue, (Oct 2, 2020)
Pfizer's Medical Affairs Lead, Rare Diseases, talks about purpose, patients and pharma's power to do good
Commercial
-
Accelerating commercial success in CAGT
To build on the successes thus far in cell and gene therapy, pharma must foster further payer, physician and patient buy-in -
Blended and augmented: Reimagining the role of the rep
The events of 2020 have compelled pharma to reimagine the role of the rep to better adapt to the new rules of engagement -
Uncorking the compliance bottlenecks in digital
The sudden demand for digital content this year has created serious compliance bottlenecks that pharma is racing to overcome with new processes and technology -
Creating a holistic customer experience
Finding solutions to unmet customer needs means harnessing the combined power of medical and marketing skills – and creating a culture to match -
Adapting to the multichannel imperative: A special report
Pharma’s gradual evolution into digital-first commercial has become urgent in the COVID-19 world. A comprehensive multi-channel approach including the use of digital tools to enhance customer engagement will transform pharma sales.
Access and Evidence
-
A burning desire to make a difference for patients
Annexus Health, eyeforpharma’s 2020 Health Start-up winner is on a mission for patients -
From reactive to predictive: Concerto’s new compositions
Artificial Intelligence has only just begun to unlock high value innovation. The latest predictive tools will break new ground, says Concerto HealthAI’s Jeff Elton -
Evolving HTA frameworks to accelerate innovation
Iterative evidence generation and demonstrating value over time could help unlock delays in getting cures out, saving more lives, says Janssen’s Clare Hague -
Can we afford to pay for future cures?
Medical innovation is racing ahead of healthcare’s ability to innovate on payments, but new ideas are emerging -
Advancing RWE together with academia
Pharma can realise the potential of RWE faster by collaborating more effectively with academia but first it must build trust
Patients and Medical
-
The value in measuring the patient experience
Pharma can improve outcomes, products and HCP relationships using technology to capture patients’ day-to-day experience of their disease -
Better research through patient insights
AstraZeneca’s innovations in chronic kidney disease are pointing the way to new ways of involving patients and RWE to drive new insights and better outcomes -
Building a health equity culture
Health inequities, often a legacy of racism, lie heavy on the healthcare sector in the US and beyond. Fixing the problem will require long-term effort on multiple fronts -
Digital companions: helping improve patient treatment journeys
The virtual health explosion isn't going away. This just at the start of an era of digital enhancement -
Racially diverse clinical trials: A new patient-led legacy takes root
Attempts to make trials more diverse aren’t working. To overcome far-reaching inequality and deep distrust, pharma must be educated by, as well as educate, under-served communities
Latest Videos
Upcoming events
View All EventsApril 2021
-
FREE WEBINAR: RWE Refined: Novel uses across the pharma value chain
Apr 13, 2021 - Apr 13, 2021
-
Pharma Customer Engagement Europe
Apr 20, 2021 - Apr 22, 2021
Digital Conference, Networking & Exhibition
May 2021
-
Healthcare Data & Informatics Week
May 4, 2021 - May 7, 2021
-
FREE WEBINAR: Build a data-driven healthcare organization
May 4, 2021 - May 4, 2021
-
FREE WEBINAR: Health Interoperability: Threats and opportunities
May 5, 2021 - May 5, 2021
-
Pharma USA (formerly eyeforpharma Philadelphia)
May 25, 2021 - Jun 4, 2021
Digital Conference, Networking and Exhibition
June 2021
September 2021
October 2021
-
Pharma Europe (formerly eyeforpharma Barcelona)
Oct 12, 2021 - Oct 22, 2021
Digital Conference, Exhibition & Networking